We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Coagulation Properties of Fresh Blood Lasts Longer Than Assumed

By LabMedica International staff writers
Posted on 17 Mar 2011
The blood clotting properties of refrigerated whole blood may have a shelf life well beyond the current standard of 24 to 48 hours.

The majority of patients receiving blood transfusions only require specific components of whole blood, such as red blood cells, plasma and platelets and the coagulation properties are thought to decline rapidly.

A study carried out at The Children's Hospital of Philadelphia, (Philadelphia, PA, USA), examined the freshness of whole blood with respect to its clotting properties in 21 units of blood from healthy volunteer donors. The units of blood were stored under standard conditions as mandated by the American Association of Blood Banks, (AABB; Bethesda, MD, USA). Samples were obtained on the day after donation and again on days 2, 4, 7, 11, 14, 17, 21, 24, and 31. Tests included complete blood count, pH, partial pressures of oxygen and carbon dioxide (pO2, pCO2), glucose, lactate, thromboelastography (TEG), and platelet function by light transmission aggregometry (LTA).

The current practice at The Children's Hospital of Philadelphia assumes a fresh whole blood shelf life of 48 hours when refrigerated. After that point, the erythrocytes may be recovered from the whole blood, but the other components, such as plasma and platelets must be discarded. However, the scientists found that TEG and platelet aggregation levels, which measure the efficiency of blood coagulation, remain normal at least 11 days under standard refrigerated conditions.

David Jobes, MD, a cardiothoracic anesthesiologist at the hospital, said, "Trauma patients could potentially benefit, as well as others needing a large volume of blood replacement, such as patients undergoing liver transplant or children who need craniofacial reconstruction. The results of the study strongly suggest that clinical trials should proceed to test the value of whole blood beyond a 48-hour period." The study was published in January 2011, in the journal Transfusion.

Related Links:

The Children's Hospital of Philadelphia

American Association of Blood Banks





Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.